Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells

European Journal of Clinical Investigation

Volumn 39, Issue 2, 2009, Pages 157-164

  Wang, A C ^a,b   Su, Q B ^a,b   Wu, F X ^a   Zhang, X L ^a,b   Liu, P S ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Chemotherapy; MyD88; Ovarian cancer; Paclitaxel; TLR4

Indexed keywords

CASPASE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PACLITAXEL; PROTEIN KINASE B; SHORT HAIRPIN RNA; TOLL LIKE RECEPTOR 4; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; EXPRESSION VECTOR; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; FEMALE; HUMANS; MYELOID DIFFERENTIATION FACTOR 88; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-AKT; TOLL-LIKE RECEPTOR 4; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 58649113433     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.02070.x     Document Type: Article

References (44)

1. Anderson KV, Bokla L, Nüsslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 1985 42 : 791 8.
2. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003 21 : 335 76.
3. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004 303 : 1522 6.
4. Zhande R, Dauphinee SM, Thomas JA, Yamamoto M, Akira S, Karsan A. FADD negatively regulates lipopolysaccharide signaling by impairing interleukin-1receptor-associated kinase 1-MyD88 interaction. Mol Cell Biol 2007 27 : 7394 404.
5. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006 66 : 3859 68.
6. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004 431 : 405 6.
7. Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G. Cancers take their Toll-the function and regulation of Toll-like receptors in cancer cells. Oncogene 2008 27 : 225 33.
8. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007 44 : 2850 9.
9. Yusuf N, Nasti TH, Long JA, Naseemuddin M, Lucas AP, Xu H et al. Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res 2008 68 : 615 22.
10. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC Jr. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994 1 : 181 90.
11. Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russell SE. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001 194 : 68 75.
12. Mao HL, Liu PS, Zheng JF, Zhang PH, Zhou LG, Xin G et al. Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro. Pharmacol Res 2007 56 : 483 92.
13. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001 31 : 2448 57.
14. Lord KA, Hoffman-Liebermann B, Liebermann DA. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene 1990 5 : 1095 7.
15. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997 278 : 1612 5.
16. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998 9 : 143 50.
17. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999 11 : 115 22.
18. Björkbacka H, Fitzgerald KA, Huet F, Li X, Gregory JA, Lee MA et al. The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades. Physiol Genomics 2004 19 : 319 30.
19. Pathak SK, Basu S, Bhattacharyya A, Pathak S, Kundu M, Basu J. Mycobacterium tuberculosis lipoarabinomannan-mediated IRAK-M induction negatively regulates Toll-like receptor-dependent interleukin-12 p40 production in macrophages. J Biol Chem 2005 280 : 42794 800.
20. Weindl G, Naglik JR, Kaesler S, Biedermann T, Hube B, Korting HC et al. Human epithelial cells establish direct antifungal defense through TLR4-mediated signalling. J Clin Invest 2007 117 : 3664 72.
21. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 2000 32 : 1123 36.
22. Holcik M, Gibson H, Korneluk RG. XIAP apoptotic brake and promising therapeutic target. Apoptosis 2001 6 : 253 61.
23. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001 61 : 1862 8.
24. Xu G, Zhou H, Wang Q, Auersperg N, Peng C. Activin receptor-like kinase 7 induces apoptosis through up-regulation of Bax and down-regulation of Xiap in normal and malignant ovarian epithelial cell lines. Mol Cancer Res 2006 4 : 235 46.
25. Xu G, Zhong Y, Munir S, Yang BB, Tsang BK, Peng C. Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7. J Clin Endocrinol Metab 2004 89 : 5523 34.
26. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001 1 : 135 45.
27. Abrahams VM, Bole-Aldo P, Kim YM, Straszewski-Chavez SL, Chaiworapongsa T, Romero R et al. Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol 2004 173 : 4286 96.
28. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971 93 : 2325 7.
29. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979 277 : 665 7.
30. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol 1982 94 : 688 96.
31. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003 21 : 3194 200.
32. Ding AH, Porteu F, Sanchez E, Nathan CF. Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 1990 248 : 370 2.
33. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006 25 : 4798 811.
34. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. AKT2 inhibition of cisplatininduced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 2003 278 : 23432 40.
35. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004 279 : 5405 12.
36. Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM et al. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 2004 23 : 706 15.
37. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005 9 : 59 71.
38. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002 5 : 234 48.
39. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005 94 : 29 86.
40. Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J 2004 5 : 489 95.
41. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004 10 : 3737 44.
42. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006 13 : 179 88.
43. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000 60 : 5659 66.
44. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM et al. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 2005 8 : 108 18.